FDA Selects Agilent’s Dual-Mode Platform for MAQC Project
News Jan 13, 2006
The U.S. Food and Drug Administration has recently selected Agilent’s dual-mode platform as part of its Microarray Quality Control (MAQC) project, designed to provide quality control guidance to the microarray industry.
"Our vision is to be able to assess the proficiency of a laboratory in running good microarray experiments," said Dr. Leming Shi, computational chemist, National Center for Toxicological Research, FDA, and architect of the MAQC project.
"We’re glad to see Agilent in the project, and we see positive responses to the one-color data from Agilent. Experimental design is unified, compared with other platforms, so there’s a lot of value in having two sample mixtures to evaluate the platform."
"This is the first one-color data I’ve ever generated, and I’m excited about using it to make research decisions," said FDA scientist Tucker Patterson, Ph.D.
"The workflow is very similar to the two-color work we’ve been doing, so there’s been no disruption caused by the new platform."
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE